Acute megakaryoblastic leukemia (AMKL) is a rare, fast-growing type of acute myeloid leukemia (AML) in which the cancerous cells are megakaryoblasts, the immature precursors of the cells that make platelets. It mainly affects young children, especially children with Down syndrome, and less commonly adults. Diagnosis needs a bone marrow test with special markers, because the cells look like other blasts and the marrow is often scarred. Outlook varies widely: children with Down syndrome usually do well with gentler chemotherapy, while other forms often need intensive treatment and a stem cell transplant.
What Is Acute Megakaryoblastic Leukemia?
Blood cells are made in the bone marrow. Normally, megakaryoblasts mature into large cells called megakaryocytes, which shed fragments into the blood as platelets. In AMKL this process stalls: abnormal megakaryoblasts multiply, fail to mature, and crowd out normal blood production.
In the older French-American-British (FAB) system, AMKL was called AML M7. In the World Health Organization framework, it is defined by at least 20% blasts in the marrow or blood, with at least half of those blasts showing megakaryocytic features. Current classifications also place many cases into genetically defined groups, which matter more for treatment than the cell type alone.
Who Gets AMKL? Types and Genetic Drivers
AMKL is best understood as several different diseases that share a cell type. The main groups are summarized below.
| Group | Typical patient | Key genetic feature | General outlook |
|---|---|---|---|
| Myeloid leukemia of Down syndrome | Children with Down syndrome, usually under 4–5 years | Acquired GATA1 mutation on top of the extra chromosome 21 | Favorable with reduced-intensity chemotherapy |
| Infant AMKL with t(1;22) | Infants without Down syndrome | RBM15::MRTFA fusion | Intermediate |
| Pediatric AMKL with other fusions | Children without Down syndrome | For example CBFA2T3::GLIS2, NUP98 or KMT2A rearrangements | Often poor; transplant commonly considered |
| Adult AMKL | Adults, often older | Frequently complex karyotype, prior myelodysplasia or prior chemotherapy | Generally poor |
The Down syndrome connection
Newborns with Down syndrome can develop a condition called transient abnormal myelopoiesis (TAM), in which megakaryoblasts carrying a GATA1 mutation appear in the blood. TAM usually resolves on its own within weeks to months, but some of these children go on to develop AMKL in early childhood. For that reason, babies who had TAM are followed with regular blood counts.
Unlike some other leukemias, AMKL has no clearly established lifestyle or environmental cause in children. In adults, earlier chemotherapy or radiation and a prior marrow disorder are recognized risk factors.
Signs and Symptoms
The symptoms come from marrow failure, organ infiltration, and scarring. They overlap with many other hematological disorders, which is why blood tests are essential.
- Anemia: tiredness, pallor, breathlessness, and poor feeding or irritability in young children.
- Low platelets: easy bruising, petechiae, nosebleeds, or gum bleeding. Platelet counts can occasionally be normal or high early on.
- Low healthy white cells: recurrent fevers and infections.
- Organ enlargement: a swollen liver or spleen, causing a full or distended abdomen.
- Bone pain: especially in children.
How AMKL Is Diagnosed
AMKL is one of the harder leukemias to diagnose, because megakaryoblasts can resemble lymphoblasts or other myeloid blasts, and because the marrow is often fibrotic.
- Complete blood count and smear: shows cytopenias and blasts, which may have cytoplasmic “blebs” or budding.
- Bone marrow aspirate and trephine biopsy: the aspirate is often a “dry tap” because of marrow fibrosis, so the biopsy core is essential.
- Flow cytometry and immunohistochemistry: megakaryoblasts express platelet glycoproteins such as CD41 and CD61, and are usually negative for myeloperoxidase.
- Cytogenetics and molecular testing: karyotyping, FISH, and sequencing identify fusions and GATA1 mutations that define the subtype and guide treatment.
AMKL is a myeloid leukemia and should not be confused with lymphoid leukemias such as Philadelphia chromosome-positive acute lymphoblastic leukemia, which have different markers, genetics, and treatments.
Treatment Options
Myeloid leukemia of Down syndrome
These leukemia cells are unusually sensitive to cytarabine, a standard AML drug. Children with Down syndrome are also more vulnerable to chemotherapy side effects, such as infections and heart toxicity. Treatment protocols therefore use lower-intensity chemotherapy, and stem cell transplantation is rarely needed in first remission.
AMKL without Down syndrome
Treatment follows intensive AML protocols, usually combining cytarabine with an anthracycline for induction, followed by consolidation. For patients with high-risk genetics, persistent disease after induction, or relapse, allogeneic hematopoietic stem cell transplantation from a matched donor is often recommended once remission is achieved.
Supportive care
Transfusions of red cells and platelets, infection prevention and prompt antibiotics, and nutrition support are central throughout treatment. Clinical trials are exploring therapies aimed at specific fusion proteins and pathways, and eligible patients may be offered a trial.
When to See a Doctor
Because AMKL often affects very young children, parents are usually the first to notice something is wrong. Arrange a prompt medical review, with a blood count, if a child has:
- Unexplained bruises, pinpoint red spots, or bleeding gums
- Persistent pallor, tiredness, or poor feeding
- Repeated fevers or infections that are slow to clear
- A swollen or firm abdomen, or bone pain that wakes them at night
Parents of a child with Down syndrome who had transient abnormal myelopoiesis as a newborn should keep up the scheduled blood count checks, even when the child seems well. Adults with a history of myelodysplasia or previous chemotherapy should report new bruising, infections, or fatigue to their hematology team without delay.
Key Takeaways
- AMKL is a rare AML subtype arising from platelet-precursor cells.
- It is most common in young children, particularly those with Down syndrome.
- Diagnosis relies on a marrow biopsy, CD41 and CD61 markers, and genetic testing.
- Down syndrome-associated AMKL usually responds well to gentler chemotherapy.
- Other forms often need intensive chemotherapy and may need a stem cell transplant.
For an overview of all leukemia types, visit our leukemia guide.
Frequently Asked Questions
Is acute megakaryoblastic leukemia curable?
Many children with Down syndrome-associated AMKL are cured with chemotherapy alone. For other children and for adults, cure is possible but harder, and often depends on reaching remission and proceeding to a stem cell transplant.
Why is AMKL linked to Down syndrome?
The extra copy of chromosome 21 changes how blood cells develop before birth. When a GATA1 mutation is added, megakaryoblasts can grow abnormally, first as transient abnormal myelopoiesis in newborns and sometimes later as AMKL.
What is a “dry tap” in AMKL?
A dry tap happens when a needle cannot draw liquid marrow because the marrow is filled with scar-like fibrous tissue. It is common in AMKL, so doctors rely on a solid core biopsy to make the diagnosis.
How is AMKL different from other types of AML?
The leukemic cells are megakaryoblasts rather than other myeloid precursors, they carry platelet markers such as CD41 and CD61, and the disease has its own set of genetic drivers. It also shows a distinctive link to young children and Down syndrome.
